There is an urgent need for therapeutic interventions for desensitization and antibody-
mediated rejection (AMR) in sensitized patients with preformed or de novo donor-specific …

The broadly human leukocyte antigen (HLA) sensitized patient awaiting organ
transplantation remains a persistent and significant problem for transplant medicine …

The presence of anti-human leucocyte antigen (HLA) antibodies in the potential solid organ
transplant recipient's blood is one of the main barriers to access to a transplantation. The …

Although solid organ transplant results have improved significantly in recent decades, a
pivotal cause of impaired long-term outcome is the development of antibody-mediated …

Major advancements in the development of HLA antibody detection techniques and our
understanding of the outcomes of solid organ transplant in the context of HLA antibody have …

Donor‐specific antibodies (DSA) form a significant barrier in solid organ transplantation of
highly pre‐sensitized candidates. Although avoiding transplantation over a positive cross …

Background. Highly HLA-sensitized (HS) patients have an increased risk for the
development of donor-specific antibodies (DSA) and antibody-mediated rejection (AMR) …

Heart transplant candidates sensitized to HLA antigens wait longer for transplant, are at
increased risk of dying while waiting, and may not be listed at all. The increasing prevalence …

Up to one third of candidates for organ or hematopoietic stem cell transplantation in the
United States have antibodies to histocompatibility antigens, the most problematic of which …

The impact of donor specific HLA antibodies (DSA) on solid organ transplant outcomes has
been recognised for over half a century. This article reviews the mechanisms of DSA …